Geode Capital Management
SRPT icon

Geode Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Geode Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.8M Buy
2,771,758
+782,962
+39% +$14.8M ﹤0.01% 1630
2026
Q1 		$43.3M Buy
1,988,796
+84,471
+4% +$1.63M ﹤0.01% 1573
2025
Q4 		$41M Buy
1,904,325
+183,201
+11% +$3.86M ﹤0.01% 1619
2025
Q3 		$33.2M Sell
1,721,124
-154,873
-8% -$2.76M ﹤0.01% 1729
2025
Q2 		$32.1M Buy
1,875,997
+55,076
+3% +$2.35M ﹤0.01% 1688
2025
Q1 		$116M Buy
1,820,921
+114,568
+7% +$12.1M 0.01% 893
2024
Q4 		$208M Buy
1,706,353
+9,999
+0.6% +$1.23M 0.02% 629
2024
Q3 		$212M Buy
1,696,354
+44,306
+3% +$6.12M 0.02% 615
2024
Q2 		$261M Buy
1,652,048
+131,678
+9% +$16.9M 0.02% 515
2024
Q1 		$197M Buy
1,520,370
+50,833
+3% +$6.23M 0.02% 598
2023
Q4 		$142M Buy
1,469,537
+60,762
+4% +$5.83M 0.01% 679
2023
Q3 		$171M Buy
1,408,775
+20,692
+1% +$2.34M 0.02% 570
2023
Q2 		$159M Buy
1,388,083
+126,112
+10% +$16.3M 0.02% 584
2023
Q1 		$174M Buy
1,261,971
+43,239
+4% +$5.61M 0.02% 548
2022
Q4 		$158M Buy
1,218,732
+64,434
+6% +$7.47M 0.02% 552
2022
Q3 		$128M Buy
1,154,298
+14,915
+1% +$1.5M 0.02% 603
2022
Q2 		$85.4M Sell
1,139,383
-9,287
-0.8% -$683K 0.01% 766
2022
Q1 		$89.7M Buy
1,148,670
+16,614
+1% +$1.27M 0.01% 844
2021
Q4 		$102M Buy
1,132,056
+147,103
+15% +$12.6M 0.01% 815
2021
Q3 		$91.1M Buy
984,953
+665
+0.1% +$51.2K 0.01% 856
2021
Q2 		$76.5M Buy
984,288
+14,525
+1% +$1.1M 0.01% 965
2021
Q1 		$72.2M Buy
969,763
+30,880
+3% +$2.85M 0.01% 951
2020
Q4 		$160M Buy
938,883
+52,302
+6% +$7.75M 0.03% 530
2020
Q3 		$124M Sell
886,581
-6,545
-0.7% -$995K 0.02% 535
2020
Q2 		$143M Buy
893,126
+42,320
+5% +$5.76M 0.03% 464
2020
Q1 		$83.2M Buy
850,806
+63,996
+8% +$7.32M 0.02% 559
2019
Q4 		$101M Buy
786,810
+28,680
+4% +$2.89M 0.02% 597
2019
Q3 		$57.1M Buy
758,130
+15,879
+2% +$1.88M 0.01% 816
2019
Q2 		$113M Buy
742,251
+49,567
+7% +$6.02M 0.03% 530
2019
Q1 		$82.6M Buy
692,684
+33,931
+5% +$4.36M 0.02% 612
2018
Q4 		$71.9M Buy
658,753
+67,601
+11% +$8.45M 0.02% 589
2018
Q3 		$95.5M Buy
591,152
+13,587
+2% +$1.86M 0.03% 544
2018
Q2 		$76.3M Sell
577,565
-1,827
-0.3% -$172K 0.02% 586
2018
Q1 		$42.9M Buy
579,392
+19,936
+4% +$1.33M 0.01% 808
2017
Q4 		$31.1M Buy
559,456
+13,631
+2% +$722K 0.01% 959
2017
Q3 		$24.8M Buy
545,825
+99,556
+22% +$3.98M 0.01% 1076
2017
Q2 		$15M Buy
446,269
+25,222
+6% +$821K 0.01% 1404
2017
Q1 		$12.5M Buy
421,047
+29,603
+8% +$916K 0.01% 1475
2016
Q4 		$10.7M Buy
391,444
+41,926
+12% +$1.68M 0.01% 1516
2016
Q3 		$21.5M Buy
349,518
+55,080
+19% +$1.67M 0.01% 953
2016
Q2 		$5.61M Buy
294,438
+12,146
+4% +$225K ﹤0.01% 1832
2016
Q1 		$5.51K Sell
282,292
-2,489
-0.9% -$43.5K ﹤0.01% 1806
2015
Q4 		$11M Buy
284,781
+34,677
+14% +$1.12M 0.01% 1316
2015
Q3 		$8.03M Buy
250,104
+6,531
+3% +$222K ﹤0.01% 1492
2015
Q2 		$7.41M Buy
243,573
+19,384
+9% +$396K ﹤0.01% 1630
2015
Q1 		$2.98M Buy
224,189
+6,614
+3% +$88.2K ﹤0.01% 2180
2014
Q4 		$3.15M Buy
217,575
+1,631
+0.8% +$27.6K ﹤0.01% 2119
2014
Q3 		$4.55M Sell
215,944
-1,853
-0.9% -$41.8K ﹤0.01% 1822
2014
Q2 		$6.49M Buy
217,797
+24,959
+13% +$789K ﹤0.01% 1623
2014
Q1 		$4.63M Buy
192,838
+21,025
+12% +$536K ﹤0.01% 1823
2013
Q4 		$3.5M Buy
171,813
+27,933
+19% +$830K ﹤0.01% 1954
2013
Q3 		$6.79M Buy
143,880
+18,442
+15% +$710K 0.01% 1345
2013
Q2 		$4.77M Buy
+125,438
New +$4.49M ﹤0.01% 1445

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management's SRPT Position: Q2 2026 in Review

Geode Capital Management increased its Sarepta Therapeutics (SRPT) stake by 39% in Q2 2026, buying an estimated $14.8M and bringing the position to 2,771,758 shares worth $49.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1630.

Geode Capital Management first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $261M in Q2 2024. 298 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Geode Capital Management held 2,771,758 shares of Sarepta Therapeutics worth $49.8M as of Q2 2026.
  • Geode Capital Management bought 782,962 Sarepta Therapeutics shares in Q2 2026, an estimated $14.8M.
  • Sarepta Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1630 holding.
  • Geode Capital Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • Geode Capital Management's Sarepta Therapeutics position peaked at $261M in Q2 2024.
  • 298 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.